Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
Author:
Affiliation:
1. Division of Clinical Pharmacology, Center for Interdisciplinary Research on Medicines (CIRM), Liège University, Liège, Belgium
2. Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Liège, Liège, Belgium
Publisher
Informa UK Limited
Subject
Pharmacology (medical),General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/14740338.2020.1733967
Reference120 articles.
1. Changes in Diabetes-Related Complications in the United States, 1990–2010
2. Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
3. Diabetic Kidney Disease: A Report From an ADA Consensus Conference
4. Preventing and treating kidney disease in patients with type 2 diabetes
5. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Antidiabetic Advancements In Silico: Pioneering Novel Heterocyclic Derivatives through Computational Design;Current Signal Transduction Therapy;2024-07
2. Saxagliptin/dapagliflozin is non‐inferior to insulin glargine in terms of β‐cell function in subjects with latent autoimmune diabetes in adults: A 12‐month, randomized, comparator‐controlled pilot study;Diabetes, Obesity and Metabolism;2024-01-31
3. Association of Sodium-Glucose Cotransporter 2 Inhibitors with Osteomyelitis and Other Lower Limb Safety Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials;Journal of Clinical Medicine;2023-06-09
4. The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review;Expert Review of Endocrinology & Metabolism;2023-05-08
5. Impact of baseline kidney function on the effects of sodium‐glucose co‐transporter‐2 inhibitors on kidney and heart failure outcomes: A systematic review and meta‐analysis of randomized controlled trials;Diabetes, Obesity and Metabolism;2023-02-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3